Project Helix – Dual-Engine Health Platform

Dear Searchfunder Community, We are pleased to introduce Project Helix, a compelling early-stage investment opportunity in a scientifically differentiated health platform operating across two synergistic divisions: OTC consumer health and Rx pharmaceuticals. Founded in 2024 by a seasoned pharmacist-entrepreneur with a prior exit to a top-tier regional pharma group, Project Helix has already launched two clinically backed OTC brands in the UK and US markets, while advancing 23 proprietary Rx dossiers through regulatory approval. Transaction Overview Capital Raise: $2M growth equity Equity Offered: 30% Pre-Money Valuation: $6.67M Use of Funds: Shareholder buyout, OTC marketing blitz, working capital expansion Investment Highlights Dual-Engine Model: Revenue-generating OTC brands and a deep Rx pipeline targeting underserved therapeutic niches Scientific Edge: ~95% bioavailability in mineral supplements; clinically validated cognitive health formulations Inventory Advantage: $5M+ in finished goods ready for scale; zero-risk entry for incoming capital Market Opportunity: $10B+ regional pharma market with strong localization incentives Financial Visibility: 2026E EBITDA of $890K; projected $67M EBITDA by 2030 Exit Strategy: IPO within 5 years; credible path to $1B+ valuation Why Engage Now? Project Helix offers asymmetric upside through a clean cap table, proven OTC traction, and a high-margin Rx pipeline. With 8 Rx dossiers already filed and 5,000+ pharmacy channels active, the company is executing at a pace and scale rarely seen at this stage. If you are interested in learning more or exploring participation in this round, please reach out directly for access to the full teaser and financial model. redacted Warm regards, George Partner